Molecular results are in line with previous reports13,19,20,24 except for ASXL1 mutations (5%), described in 26% of t-MDS24 and 17% of t-AML.13 We found a higher frequency of TP53 (31%) mutations and lower frequency of NPM1 (10%) and FLT3 (9%) in TRMN compared to de novo AML/MDS as described by others.13,19,21,24 More interestingly, we described 9% of PPM1D mutations, a gene usually not included in myeloid NGS panels. The gene discussed is TP53; the disease is acute myeloid leukemia.